Lessons learned from our preliminary experience with MiLEP: a retrospective analysis of efficacy and safety using slim and ultra-slim instruments.

Purpose: Minimally invasive laser enucleation of the prostate has emerged as a promising treatment for benign prostatic hyperplasia. This study investigates the efficacy and safety of miniaturized holmium laser enucleation of the prostate (MiLEP) using Slim (22 Fr) and Ultra-Slim HoLEP (18.5 Fr).

Surgical treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: an analysis and meta-synthesis of available guidelines.

Purpose: The increase in minimally invasive treatments (MITs) for lower urinary tract symptoms secondary to benign prostatic obstruction (LUTS/BPO) has diversified surgical options, often outpacing solid evidence. The variety of available treatments, while beneficial, can confound physicians. Clinical guidelines provide direction but often differ due to varied evidence interpretation.

Prognostic Factors for Pregnancy and Patency Rates After Microsurgery for Obstruction of the Upper Seminal Tract: A Retrospective Single-surgeon Series of 336 Cases.

Background And Objective: To achieve optimal results in treating vasal obstruction, microsurgery is the standard of care. However, not all vasovasostomy (VV) or vasoepididymostomy (VE) procedures lead to subsequent pregnancy. Identification of parameters that can predict success in restoring fertility is clinically relevant.

Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Obstruction: 5-year Outcomes of a Randomised, Open-label, Noninferiority Trial.

Background And Objective: Prostatic artery embolisation (PAE) and transurethral resection of the prostate (TURP) are two of the surgical options for treatment of lower urinary tract symptoms/benign prostatic obstruction (LUTS/BPO). Our aim was to compare the efficacy and safety of PAE and TURP for LUTS/BPO treatment at long-term follow-up.

Methods: We conducted a randomised, open-label, single-centre trial at a Swiss tertiary care centre.